Related Experiment Video
Updated: Mar 13, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Immunogenic decapeptide in melanoma immunotherapy
Navnit Kumar Mishra1, Anil Kumar Sharma2, Tapan Kumar Mukherjee2
1Department of Biotechnology, Maharishi Markandeshwar University, Mullana (Ambala), Haryana, 133207, India. navnitchem@yahoo.com.
Abstract:
Melanoma is a cancer associated with melanocytes of epidermis. There has been a consistent increase in the number of melanoma patients because of the depletion of the ozone layer which makes it of paramount importance to explore the immunogenic potential of various peptides in melanoma therapy. In the current study, a mutated decapeptide (ELAGIGILTV) epitope ID 12941 was taken from the melanoma antigen recognized by T-cells. This epitope displayed relatively better affinity for histocompatibility leukocyte antigen influencing the proliferation of cytotoxic T-cells. Immunogenicity of the oligopeptide can be further intensified by its simultaneous binding to the programmed death receptor of the T lymphocytes. We have used the molecular dynamics (MD) simulation approach to reveal the dynamics of the decapeptide and its consequences to immunogenic effects. The dynamics have ensembled various conformations of the peptide which have been clustered in their representative conformers. During the dynamics, the peptide was found to fold to its conformation with a minimum free energy. Moreover, multiple analysis of the MD trajectory has provided many physiochemical features involved in the biological activity to improve the immunogenicity of this antigenic peptide. The manuscript concludes by proposing this decapeptide as a potential vaccine for the melanoma cancer.
Insights
Researchers explored a mutated decapeptide for melanoma therapy. Molecular dynamics simulations revealed its potential to enhance T-cell responses, proposing it as a promising melanoma cancer vaccine candidate.
Area of Science:
- Immunology
- Computational Biology
- Oncology
Background:
- Melanoma incidence is rising, necessitating novel therapeutic strategies.
- Peptide-based immunotherapy holds promise for melanoma treatment.
- Understanding T-cell interactions with melanoma antigens is crucial.
Purpose of the Study:
- To investigate the immunogenic potential of a mutated decapeptide (epitope ID 12941) derived from melanoma antigens.
- To explore the peptide's interaction with histocompatibility leukocyte antigen (HLA) and its effect on cytotoxic T-cell proliferation.
- To assess the feasibility of enhancing peptide immunogenicity through programmed death receptor binding.
Main Methods:
- Utilized molecular dynamics (MD) simulations to analyze the decapeptide's conformational dynamics.
- Employed clustering analysis to identify representative peptide conformers.
- Performed physicochemical analysis of MD trajectories to understand biological activity.
Main Results:
- The decapeptide (ELAGIGILTV) exhibited favorable affinity for HLA, promoting cytotoxic T-cell proliferation.
- MD simulations revealed the peptide's tendency to fold into a minimum free energy conformation.
- Analysis identified key physicochemical features contributing to the peptide's enhanced immunogenicity.
Conclusions:
- The mutated decapeptide demonstrates significant potential for melanoma immunotherapy.
- Its ability to interact with HLA and potentially programmed death receptors warrants further investigation.
- This decapeptide is proposed as a candidate for a melanoma cancer vaccine.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...